TuHURA Biosciences, Inc. Common Stock
Veridion Score
Composite trend over time
Why is HURA moving today?
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for HURA.
HURA insider activity
TuHURA Biosciences, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for HURA.
HURA contract awards, year to date.
Public federal awards linked to this ticker.
HURA lobbying filings, year to date.
Registered lobbying filings matched to TuHURA Biosciences, Inc. Common Stock.